Reldesemtiv Emerging Drug Insight and Market Forecast - 2032

“Reldesemtiv Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about Reldesemtiv for Amyotrophic Lateral Sclerosis in the 7MM. A detailed picture of the Reldesemtiv for Amyotrophic Lateral Sclerosis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the Reldesemtiv for Amyotrophic Lateral Sclerosis. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Reldesemtiv market forecast, analysis for Amyotrophic Lateral Sclerosis in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in Amyotrophic Lateral Sclerosis.

Drug Summary

Reldesemtiv (CK-2127107) is a fast skeletal muscle troponin activator (FSTA) with the potential to treat people living with debilitating diseases and conditions associated with muscle weakness and/or muscle fatigue, including ALS and spinal muscular atrophy (SMA). It is an investigational drug candidate intended to slow the rate of calcium release from the regulatory troponin complex of fast skeletal muscle fibers. The skeletal muscles' contraction is driven by the sarcomere, the fundamental unit of muscle contraction, which contains myosin. This protein converts chemical energy into mechanical force through its interaction with another protein, actin. This interaction is regulated by other proteins, including troponin and tropomyosin, and depends on calcium changes. By slowing the rate of calcium release, reldesemtiv sensitizes the sarcomere to calcium, leading to increased muscle contractility.

In 2013, Cytokinetics and Astellas formed a partnership focused on the research, development, and potential commercialization of skeletal muscle activators, including reldesemtiv. It was granted orphan drug designation by the US FDA in 2019 and orphan medicinal product designation by the European Medicines Agency for the potential treatment of ALS in 2020. In March 2019, a Phase II trial” FORTITUDE-ALS” was completed. The results were announced in May 2019, which stated that the trial did not achieve statistical significance for its primary efficacy analysis. A Phase III COURAGE-ALS (Clinical Outcomes Using Reldesemtiv on ALSFRS-R in a Global Evaluation in ALS) is currently recruiting patients with ALS.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the Reldesemtiv description, mechanism of action, dosage and administration, research and development activities in Amyotrophic Lateral Sclerosis.
• Elaborated details on Reldesemtiv regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Reldesemtiv research and development activity in Amyotrophic Lateral Sclerosis details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around Reldesemtiv.
• The report contains forecasted sales of Reldesemtiv for Amyotrophic Lateral Sclerosis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Amyotrophic Lateral Sclerosis.
• The report also features the SWOT analysis with analyst views for Reldesemtiv in Amyotrophic Lateral Sclerosis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by a team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Reldesemtiv Analytical Perspective

In-depth Reldesemtiv Market Assessment

This report provides a detailed market assessment of Reldesemtiv in Amyotrophic Lateral Sclerosis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

Reldesemtiv Clinical Assessment

The report provides the clinical trials information of Reldesemtiv for Amyotrophic Lateral Sclerosis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Amyotrophic Lateral Sclerosis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Reldesemtiv dominance.
• Other emerging products for Amyotrophic Lateral Sclerosis are expected to give tough market competition to Reldesemtiv and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Reldesemtiv in Amyotrophic Lateral Sclerosis.
• Our in-depth analysis of the forecasted sales data of Reldesemtiv from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Reldesemtiv in Amyotrophic Lateral Sclerosis.

 

Key Questions Answered

• What is the product type, route of administration and mechanism of action of Reldesemtiv?
• What is the clinical trial status of the study related to Reldesemtiv in Amyotrophic Lateral Sclerosis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Reldesemtiv development?
• What are the key designations that have been granted to Reldesemtiv for Amyotrophic Lateral Sclerosis?
• What is the forecasted market scenario of Reldesemtiv for Amyotrophic Lateral Sclerosis?
• What are the forecasted sales of Reldesemtiv in the 7MM, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Amyotrophic Lateral Sclerosis and how are they giving competition to Reldesemtiv for Amyotrophic Lateral Sclerosis?
• Which are the late-stage emerging therapies under development for the treatment of Amyotrophic Lateral Sclerosis?